Breakthroughs
A New Drug May Double Survival in Pancreatic Cancer: What Patients Need to Know
Pancreatic cancer has long been one of oncology's most resistant frontiers. At ASCO 2026, results from the phase 3 RASolute 302 trial changed that narrative. The oral drug daraxonrasib nearly doubled survival in patients with previously treated metastatic pancreatic cancer, achieving a median overall survival of 13.2 months compared to 6.7 months with standard chemotherapy. Oncologists are calling it transformative. Here is what patients and families need to know.
